Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cellular Adaptation IV: Dysplasia and Metaplasia

Cellular Adaptation IV: Dysplasia and Metaplasia

DysplasiaDysplasia refers to abnormal changes in the size, shape, and organization of mature cells, characterized by pleomorphism, nuclear abnormalities, and increased mitotic activity. It commonly affects epithelial tissues, including the cervix, gastrointestinal tract, respiratory mucosa, and endometrium. Although it may occur alongside hyperplasia, dysplasia is not a true adaptive response but a preneoplastic change with potential to progress to cancer.When confined above the basement...

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026

Same author

Unique structural and ligand-binding properties of the <i>Staphylococcus aureus</i> serine hydrolase FphE.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Unique structural and ligand binding properties of the <i>Staphylococcus aureus</i> serine hydrolase FphE.

bioRxiv : the preprint server for biology·2025

Same author

The evolving nosology of myeloid neoplasms: the semi-centennial of the 1976 French-American-British classification.

Leukemia·2025

Same author

Chemoenzymatic Skeletal Editing of Natural Product Scaffolds via P450-Controlled Site-Selective Ring Expansion at Aliphatic C─H Sites.

Angewandte Chemie (International ed. in English)·2025

Same author

Identification of covalent inhibitors of Staphylococcus aureus serine hydrolases important for virulence and biofilm formation.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Myelodysplastic syndromes classification and risk stratification.

Rami S Komrokji¹, Ling Zhang, John M Bennett

¹H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA. rami.komrokji@moffitt.org

Hematology/Oncology Clinics of North America

|April 3, 2010

Summary

Myelodysplastic syndromes (MDS) are bone marrow failure disorders characterized by dysplasia. Current classification systems are reviewed, with future directions focusing on pathobiology and molecular signatures for improved risk stratification.

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Related Experiment Videos

Last Updated: Jun 14, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Published on: November 10, 2023

Area of Science:

Hematology
Oncology
Pathology

Background:

Myelodysplastic syndromes (MDS) are a group of heterogeneous bone marrow failure disorders.
Cytologic dysplasia is a unifying pathologic feature across MDS subtypes.
Existing classification systems for MDS have evolved with increasing understanding of the disease.

Purpose of the Study:

To review the current classification systems for Myelodysplastic syndromes (MDS).
To highlight the differences between various MDS classification and risk stratification systems.
To discuss the future direction of MDS classification towards pathobiology and molecular signatures.

Main Methods:

Review of existing literature on MDS classification and risk stratification.
Comparative analysis of different classification systems.
Discussion of emerging molecular and pathobiologic insights.

Main Results:

Current MDS classification is primarily based on morphology and cytologic dysplasia.
Various risk stratification systems exist, impacting treatment decisions.
Limitations of current systems highlight the need for evolution.

Conclusions:

The classification of Myelodysplastic syndromes (MDS) currently relies on pathologic features.
Future classification and risk stratification are expected to integrate pathobiology and molecular data.
This shift aims to provide a more precise understanding and personalized management of MDS.